Emerging and Evolving Biomarkers: NTRK
 |
 |
|---|---|
Speaker: Lynette Sholl, MD |
Moderator: Lauren Ritterhouse, MD, PhD |
Description:
Neurotrophic receptor kinase genes 1, 2 and 3 (NTRK1, NTRK2, NTKR3) encode proteins (tropomyosin receptor kinases TRKA, TRKB, and TRKC respectively) essential for neurodevelopment and neuronal function. These genes have recently been implicated as oncogenic drivers across diverse adult and pediatric tumors as a result of chromosomal rearrangement events that fuse a 5’ partner gene with the 3’ portion of an NTRK gene including the kinase domain. These fusions, while rare, predict clinical response to targeted TRK inhibitors and provide an important therapeutic avenue for patients who often have few alternative treatment options. The biology, epidemiology, and clinicopathologic correlations of NTRK fusions, as well as testing strategies to optimize detection of these fusions in practice, will be addressed in this presentation.
Learning Objectives:
- Describe the biological principles that underlie the pathogenicity of each biomarker, including the cellular signaling pathways and cellular processes involved.
- Discuss the appropriate technical approaches and platforms for molecular diagnostic testing for fusion detection and rare diseases.
- Outline the strengths and limitations of described testing approaches.
- Apply biomarker information so as to order appropriate testing and interpret biomarker status results within a clinical context.
Supported by an educational grant from Lilly (for further information concerning Lilly grant funding visit www.lillygrantoffice.com), which had no control over its content. No personally-identifiable information regarding you is provided to any grant supporters.
Recording Date: December 8, 2020
Duration: 1 hr
Level of Instruction: Basic
How to claim credit:
To earn CME/CMLE credit, all learners must watch the webinar and then complete the online survey.
AMA PRA Category 1 Credit(s)™
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.
The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.